Related Experiment Video
Updated: Mar 29, 2026
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
Novel Immune Checkpoint Inhibitor and Antibody-Drug Conjugate Approaches in the Perioperative Management of
Joseph Vento1, Tian Zhang1, Yair Lotan2
1Department of Internal Medicine, Division of Hematology & Oncology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Abstract:
Immune checkpoint inhibitors and antibody drug conjugate combinations have revolutionized the management of patients with advanced and metastatic urothelial carcinoma, offering unprecedented survival outcomes. These treatments are now moving into earlier stages of disease, including perioperative treatments for patients with muscle-invasive bladder cancer planning for curative-intent radical cystectomy. In this setting, there are now standard-of-care options for adjuvant immune checkpoint inhibitors with or without prior neoadjuvant chemotherapy, perioperative immune checkpoint plus cytotoxic chemotherapy combinations, and perioperative immune checkpoint inhibitor plus antibody drug conjugate combinations. This review will evaluate key clinical trials that led to modern standards of care involving these classes of drugs and highlight ongoing clinical trials that may further shift treatment paradigms for muscle-invasive bladder cancer. Key efficacy and toxicity considerations will be reviewed, and available evidence for biomarkers will be evaluated. As immune checkpoint inhibitors and antibody drug conjugates continue to demonstrate improved outcomes across the spectrum of bladder cancer treatment, understanding their role in the muscle-invasive disease state is crucial to managing patients with this condition.
Insights
New combinations of immune checkpoint inhibitors and antibody drug conjugates are improving outcomes for advanced urothelial carcinoma. These advanced treatments are now being used in earlier stages, including perioperative settings for muscle-invasive bladder cancer.
Area of Science:
- Oncology
- Urothelial Carcinoma Research
- Cancer Therapeutics
Background:
- Advanced and metastatic urothelial carcinoma management has been transformed by immune checkpoint inhibitors (ICIs) and antibody drug conjugates (ADCs).
- These novel therapies are increasingly being investigated and utilized in earlier disease stages, specifically for muscle-invasive bladder cancer (MIBC) requiring radical cystectomy.
- Current perioperative treatment strategies for MIBC include adjuvant ICIs, neoadjuvant chemotherapy followed by adjuvant ICIs, and combinations of ICIs with chemotherapy or ADCs.
Purpose of the Study:
- To review key clinical trials establishing current standards of care for perioperative and adjuvant treatments in MIBC.
- To highlight ongoing clinical trials exploring novel combinations and treatment sequences for MIBC.
- To evaluate efficacy, toxicity, and biomarker data for ICIs and ADCs in the context of MIBC management.
Main Methods:
- Literature review of pivotal clinical trials and ongoing studies in perioperative and adjuvant settings for MIBC.
- Analysis of efficacy and safety data from clinical trials involving ICIs and ADCs.
- Evaluation of current evidence regarding biomarkers predictive of response to these therapies.
Main Results:
- Established standards of care now incorporate adjuvant ICIs, perioperative chemo-immunotherapy, and perioperative ICI-ADC combinations for MIBC.
- Ongoing trials are investigating further refinements and novel combinations, potentially altering future treatment paradigms.
- Significant improvements in survival outcomes have been observed with these novel agents in advanced urothelial carcinoma, with growing evidence in earlier stages.
Conclusions:
- Immune checkpoint inhibitors and antibody drug conjugates represent a paradigm shift in urothelial carcinoma treatment, extending to earlier stages like MIBC.
- Understanding the role and optimal sequencing of these agents in the perioperative setting is critical for improving outcomes in MIBC.
- Continued research and biomarker evaluation are essential to further personalize and optimize treatment strategies for muscle-invasive bladder cancer.
Related Concept Videos
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...